ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0344

Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels

Shivani Garg1, Betty Chewning2, Brad Astor3 and Christie Bartels4, 1University of Madison, School of Medicine and Public Health, Madison, WI, 2University of Wisconsin, School of Pharmacy, Madison, WI, 3University of Wisconsin, School of Medicine and Public Health, Madison, WI, 4University of Wisconsin School of Medicine and Public Health, Madison, WI

Meeting: ACR Convergence 2022

Keywords: Disease Activity, Patient reported outcomes, Renal, socioeconomic factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: SLE – Treatment Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Lupus, the leading cause of chronic kidney disease (CKD) in young women, is treated with Hydroxychloroquine (HCQ) which is primarily excreted by kidneys. Yet how physiologic renal function impacts HCQ levels is unclear, and highly relevant for safety and efficacy. Lupus damage shows disparities suggesting that adverse social determinants may influence outcomes, possibly via low HCQ levels. Finally, due to misperceived risks vs. benefits, up to 83% of patients may stop HCQ highlighting the need to clarify HCQ thresholds for adherence, efficacy, and safety. We aimed to: i) examine how renal function, dose, and other factors predict change in HCQ levels, ii) clarify thresholds of HCQ levels to predict adherence, efficacy, and identify patients at-risk for toxicity.

Methods: We measured HCQ levels with liquid chromatography mass spectrometry on whole blood from consented adults with lupus on HCQ therapy for ≥1 month. We abstracted HCQ dose by weight, sociodemographics, SLE disease activity index (SLEDAI ≥6 defined lupus flare), glomerular filtration rate (GFR), CKD stage, and data on adverse social determinants: Medicaid, disadvantaged neighborhoods by area deprivation index, and reported social barriers. Patients reported adherence on a 0-100% MASRI visual analogue scale (≥80% defined adherence).

Multivariable mixed regression models assessed how renal function, adverse social determinants, and other factors predict change in HCQ levels. Based on prior studies, a clinically significant change in HCQ levels was ≥8% change in mean levels (≥64.5 ng/mL based on maximal diurnal variation). We tested four levels, ≥500, ≥750, ≥1000, and ≥1500 ng/mL, to examine thresholds of HCQ levels that indicate adherence, efficacy, and identify higher toxicity risk.

Results: The mean HCQ level across 166 samples was 806±477 ng/ml. We found that CKD stage ≥2 was associated with a clinically significant increase in HCQ levels of 149 ng/mL vs. stage 1 (Table 1). Similar findings were noted when GFR was used instead of CKD stage (Table 2).

We noted reported adherence ≥80% was associated with a 646 ng/mL increase in HCQ levels vs. < 80% adherence. Finally, 400 mg/day prescribed dose increased HCQ levels by 448 ng/mL vs. 200 mg/day after even controlling for doses >5mg/kg/day. We found that increase in body weight by 15 kg was associated with a decrease in HCQ levels by 82 ng/mL (Table 1). Adverse social determinants did not predict change in HCQ levels.

HCQ levels ≥500 ng/mL predicted 21-fold higher odds of patient-reported adherence (Table 3A). Both ≥750 ng/ml & ≥1000 ng/mL thresholds predicted ~75% lower odds of flare (Table 3B-C). We found 4-fold higher odds of HCQ levels ≥1500 ng/mL in patients with CKD stage ≥2 (Table 3D).

Conclusion: Our findings inform practice change by clarifying clinical thresholds and predictors of changes in HCQ levels. Our study is the first to report that CKD stage ≥2 predicted 4-fold higher odds of supratherapeutic levels (≥1500 ng/mL), highlighting a need for monitoring levels in CKD. Adverse social determinants did not predict lower levels. Our study validates HCQ levels ≥500 ng/mL as a good threshold to detect adherence, and HCQ levels of 750-1000 ng/mL to prevent 75% flares.

Supporting image 1

Table 1. Physiological and social predictors of change in continuous HCQ blood levels using multivariable linear regression, n = 166 samples

Supporting image 2

Table 2. Predictors of change in continuous HCQ levels using GFR vs. CKD stage, n = 166

Supporting image 3

Table 3. Multivariable odds of therapeutic HCQ levels by: A) ≥500 ng/mL; B) ≥750 ng/mL; C) ≥1000 ng/mL; D) ≥1500 ng/mL (n = 166)


Disclosures: S. Garg, None; B. Chewning, None; B. Astor, None; C. Bartels, Pfizer.

To cite this abstract in AMA style:

Garg S, Chewning B, Astor B, Bartels C. Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/therapeutic-thresholds-of-hydroxychloroquine-blood-levels-physiologic-and-social-determinants-of-low-hydroxychloroquine-blood-levels/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/therapeutic-thresholds-of-hydroxychloroquine-blood-levels-physiologic-and-social-determinants-of-low-hydroxychloroquine-blood-levels/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology